ACT Brief: AI and Ozempic's Potential
Welcome to the ACT Brief, your fast track to the latest insights in clinical research operations.
AI in Site Leadership
Artificial intelligence is helping uncover site leaders in underserved regions to strengthen trial diversity.
Ozempic's Potential
New research suggests Ozempic may reduce biological age by more than three years, beyond its known support for weight loss.
Ozempic may actually reduce biological age.
Join us tomorrow for more insights shaping the future of clinical operations and drug development.
Author's summary: AI and Ozempic advance clinical research.
More News
- Novak Djokovic makes big statement about the main stadium at the Hellenic Championship after reaching the final
- Dr. Oz jumps in as drug exec collapses during Oval Office press conference
- Katrina Kaif and Vicky Kaushal Welcome Their First Child, A Baby Boy | Outlook India
- Stranger Things 5: first 5 mins | TV Tonight
- American Legion volunteers to fly flags this weekend for Veterans Day Tuesday
- Christine Flowers: Malala’s message should echo to the White House
- Lorenzo Musetti one win away from qualifying for ATP Finals, Novak Djokovic awaits | Tennis.com
- Woman Removed From Gold's Gym After Viral Interaction With Trans Woman in Locker Room, Joey Swoll Reacts – Fitness Volt
- Remembering Highwood Museum volunteer Brian Keeling
- British grandmother on Indonesia death row arrives back in London